Nidan Laboratories and Healthcare Limited (NSE:NIDAN)
India · Delayed Price · Currency is INR 13.45
+0.30 (2.28%)
Jul 31, 2026, 12:49 PM IST
NSE:NIDAN Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 255.42 | 245.28 | 241.77 | 242.66 | 296.6 | |
Revenue Growth | 4.13% | 1.45% | -0.36% | -18.19% | 42.65% |
Cost of Revenue | 10 | 19.53 | 21.93 | 24.67 | 37.7 |
Gross Profit | 245.42 | 225.74 | 219.84 | 217.99 | 258.9 |
Selling, General & Admin | 43.02 | 47.63 | 48.62 | 51.58 | 38.54 |
Other Operating Expenses | 153.97 | 125.81 | 106.78 | 98.37 | 126.22 |
Operating Expenses | 215.97 | 197.53 | 184.06 | 180.94 | 191.07 |
Operating Income | 29.45 | 28.22 | 35.78 | 37.05 | 67.83 |
Interest Expense | -19.56 | -20.66 | -20.86 | -20.95 | -24.35 |
Interest & Investment Income | - | 20.46 | 26.46 | 28.84 | 0.05 |
Other Non Operating Income (Expenses) | 18.56 | -0.73 | 0.05 | 0.48 | -1.22 |
EBT Excluding Unusual Items | 28.44 | 27.29 | 41.44 | 45.43 | 42.31 |
Gain (Loss) on Sale of Assets | - | 0.32 | - | 2.69 | 2.89 |
Other Unusual Items | -4 | - | -65.13 | - | - |
Pretax Income | 24.44 | 27.6 | -23.69 | 48.12 | 45.2 |
Income Tax Expense | 9.38 | 7.83 | 8.64 | 12.72 | 18.58 |
Net Income | 15.06 | 19.77 | -32.32 | 35.4 | 26.63 |
Net Income to Common | 15.06 | 19.77 | -32.32 | 35.4 | 26.63 |
Net Income Growth | -23.82% | - | - | 32.92% | 15.66% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 11 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 11 |
Shares Change | 0.32% | - | - | 21.22% | 15.83% |
EPS (Basic) | 1.08 | 1.42 | -2.33 | 2.55 | 2.32 |
EPS (Diluted) | 1.08 | 1.42 | -2.33 | 2.55 | 2.32 |
EPS Growth | -23.94% | - | - | 9.76% | -0.24% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 11.9 | 13.36 | 47.84 | 103.01 | 7.53 |
Free Cash Flow Per Share | 0.85 | 0.96 | 3.44 | 7.41 | 0.66 |
Gross Margin | 96.08% | 92.04% | 90.93% | 89.83% | 87.29% |
Operating Margin | 11.53% | 11.50% | 14.80% | 15.27% | 22.87% |
Profit Margin | 5.90% | 8.06% | -13.37% | 14.59% | 8.98% |
Free Cash Flow Margin | 4.66% | 5.45% | 19.79% | 42.45% | 2.54% |
EBITDA | 48.42 | 52.26 | 64.35 | 67.9 | 94.06 |
EBITDA Margin | 18.96% | 21.31% | 26.61% | 27.98% | 31.71% |
D&A For EBITDA | 18.98 | 24.05 | 28.57 | 30.84 | 26.23 |
EBIT | 29.45 | 28.22 | 35.78 | 37.05 | 67.83 |
EBIT Margin | 11.53% | 11.50% | 14.80% | 15.27% | 22.87% |
Effective Tax Rate | 38.38% | 28.38% | - | 26.44% | 41.09% |
Revenue as Reported | 273.97 | 267.78 | 269.24 | 275.95 | 300.62 |